151. Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease.
- Author
-
Elosua González A, Sanz Segura P, Oyón Lara D, López García S, Arroyo Villarino MT, Alcalá Escriche MJ, Ollero Domenche L, Rodríguez Gutiérrez C, and Nantes Castillejo Ó
- Subjects
- Antibodies, Monoclonal, Gastrointestinal Agents therapeutic use, Humans, Infliximab therapeutic use, Prospective Studies, Remission Induction, Treatment Outcome, Biosimilar Pharmaceuticals therapeutic use, Colitis, Ulcerative drug therapy, Inflammatory Bowel Diseases drug therapy
- Abstract
Introduction: CT-P13 is a biosimilar drug of infliximab (IFX), effective in patients with inflammatory bowel disease (IBD). The monitoring of levels of IFX and anti-IFX antibodies is now considered part of the integral management., Objective: To compare the clinical response according to a strictly clinical (CLN) or proactive (PRO) approach based on the monitoring of levels in week 14, in clinical practice., Methods: We conducted a prospective study in IBD patients starting CT-P13. In the PRO group, levels of IFX and post-induction antibodies were systematically measured (week 14) and those with infraterapeutic levels (<3μg/ml) were intensified, irrespective of the clinical response., Results: We included 77 patients (23 ulcerative colitis and 54 Crohn's disease). Both PRO (n=41) and CLN (n=36) groups showed initial and long-term efficacy without significant differences. At week 14, 61% clinical remission (CR) (58.5% PRO, 63.9% CLN) and 80.5% at least partial response (PR) (80.5% PRO, 80.6% CLN). In week 54, 68.8% CR (61% PRO, 77.8% CLN) and 76.6% at least PR (73.2% PRO, 80.6% CLN). Of the patients in CR in week 14 (24 PRO, 23 CLN), 13 of the PRO group were intensified due to infra-therapeutic levels. In this subgroup no significant differences were observed in secondary loss of response (PRO 0%, CLN 8.7%)., Conclusion: Proactive management does not improve response or remission rates in the first year. The intensification of clinical remission patients with post-induction infratherapeutic levels does not seem to significantly prevent secondary loss of response in the first year., (Copyright © 2019 Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF